Health. Quality. Life.
hu en
dr. Hodász István

Dear Visitor,


Let me welcome you on Egis Pharmaceuticals PLC’s new website where you can gain information about our company’s present and its history reaching back to nearly a century, our ars poetica and our activities.

EGIS PLC is one of the leading, vertically integrated pharmaceutical companies in Central Eastern Europe with activities extending to every field of pharmaceutical production from generic and original R&D, through active ingredient and finished production to sales and marketing.

The most important key to our competitiveness and our future success is innovation, to which we dedicate an outstanding amount on a regional level as well. Among the companies present in the Central Eastern European region, we dedicate the fourth largest amount, nearly HUF 11 billion to research and development yearly. The work of our researchers is recognized by six Innovation Prizes our generic products have won.

Thanks to our products providing excellent quality, cost-effective therapies, EGIS has for a long time been a leading pharmaceutical company in the Hungarian market. Every tenth product sold in the Hungarian market is produced by us and within our traditional therapeutic field, the cardiovascular market segment our products are the most widely recommended by specialists. According to the latest surveys carried out among cardiovascular specialists, EGIS PLC is the most prestigious and most ethical pharmaceutical producer in the domestic market.

Flexibility, rapidity and efficiency are vital in competing against other pharmaceutical players; therefore our group being present in 18 countries besides Hungary is developing dynamically: we are expanding our portfolio with new products and new therapeutic areas and are opening towards new markets. Our oncology portfolio is growing and in 2010 we entered into a collaboration agreement with the South Korean Celltrion Group so that we can appear with our biosimilar products in our strategic markets at the same time with the very first biosimilar players.

I sincerely hope that my short introduction has aroused your interest and that you will find the answer to all your questions on our pages.

I wish you a pleasant visit!

Dr. István Hodász
Chief Executive Officer